Class, Biotech Co. Propose $10.65M Deal To End Merger Suit
Law 360 M&A
OCTOBER 27, 2022
Former Asterias Biotherapeutics stockholders have reached a $10.65 million deal to settle a 3-year-old Delaware Chancery Court class action challenging the company's November 2018 stock-for-stock merger agreement with allegedly controlling investor BioTime Inc.
75 
Let's personalize your content